Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volitinib (AZD6094) plus docetaxel in MET-amplified advanced gastric adenocarcinoma (second-line)
KCT0004050Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib in gastric adenocarcinoma, sponsored by AstraZeneca. Started Apr 2015; status: active, not recruiting.
02
Drugs
savolitinib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on KCT0004050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004050.